Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008:65–203. doi: 10.1007/978-3-540-73277-8_3

Pharmacology and Pharmacotherapy

Dietmar P Berger 3, Rupert Engelhardt 4, Hartmut Henß 3, Jürgen Scheele 5, Claudia I Müller 5, Alexandra Göbel 3, Beate Lubrich 6, Anna-Katharina Kaskel 3, Hendrik Veelken 5, Karin Potthoff 7, Ralph Waesch 3, Uwe Martens 3, Claudia Schmoor 8, Herbert Maier-Lenz 8, Antonia Müller 3
Editors: Dietmar P Berger1, Monika Engelhardt1, Hartmut Henß2, Roland Mertelsmann1
PMCID: PMC7119909

The content is available as a PDF (1.7 MB).

References

  • 1.Anderson CM, et al. Drug profiles. In: Perry MC, Anderson CM, Doll DC, et al., editors. Companion Handbook to the Chemotherapy Sourcebook. 2. Philadelphia: Lippincott Williams & Wilkins; 2004. pp. 419–72. [Google Scholar]
  • 2.Chauncey TR. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol. 2001;13:21–6. doi: 10.1097/00001622-200101000-00005. [DOI] [PubMed] [Google Scholar]
  • 3.Egorin MJ. Overview of recent topics in clinical pharmacology of anticancer agents. Cancer Chemother Pharmacol. 1998;42(Suppl):22–30. doi: 10.1007/s002800051076. [DOI] [PubMed] [Google Scholar]
  • 4.Fischer DS, Knobf MT, Durivage HJ, et al. The Cancer Chemotherapy Handbook. Philadelphia: Mosby; 2003. pp. 48–241. [Google Scholar]
  • 5.Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs. 2000;60(Suppl 1):1–14. doi: 10.2165/00003495-200060001-00001. [DOI] [PubMed] [Google Scholar]
  • 6.Skeel RT. Antineoplastic drugs and biological response modifiers. Classification, use and toxicity of clinically useful agents. In: Skeel RT, editor. Handbook of Cancer Chemotherapy. 6. Philadelphia: Lippincott Williams & Wilkins; 2003. pp. 53–156. [Google Scholar]
  • 1.http://www.druginfonet.com/ Drug Information, Information on Antineoplastic Agents
  • 2.http://www.meds.com/DChome.html Information on cytostatics
  • 3.http://chemfinder.cambridgesoft.com Chemical Data Base
  • 1.http://www.druginfonet.com/ Drug Information Network
  • 2.http://chemfinder.cambridgesoft.com/ Chemfinder Database
  • 3.http://www.meds.com/DChome.html Dose Calculation of Cytostatics
  • 1.Ginsberg JP, Womer WB. Preventing organ-specific chemotherapy toxicity. Eur J Cancer. 2005;41:2690–700. doi: 10.1016/j.ejca.2005.05.016. [DOI] [PubMed] [Google Scholar]
  • 2.Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474–85. doi: 10.1056/NEJMra021844. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.druginfonet.com/ Drug information
  • 2.http://www.meds.com/DChome.html Information on Cytostatics
  • 1.Bailey BJ, Briars GL. Estimating the surface area of the human body. Stat Med. 1996;15:1325–32. doi: 10.1002/(SICI)1097-0258(19960715)15:13<1325::AID-SIM233>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  • 2.Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. 2002;94:883–8. doi: 10.1093/jnci/94.24.1883. [DOI] [PubMed] [Google Scholar]
  • 3.Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 1970;54:225–35. [PubMed] [Google Scholar]
  • 4.Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098. doi: 10.1056/NEJM198710223171717. [DOI] [PubMed] [Google Scholar]
  • 5.Reilly JJ, Workman P. Normalization of anti-cancer drug dosage using body weight and surface area: is it worthwhile? Cancer Chemother Pharmacol. 1993;32:411–8. doi: 10.1007/BF00685883. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.halls.md/body-surface-area/refs.htm BSA, Formulas and Comments
  • 2.http://www.halls.md/body-surface-area/bsa.htm BSA Calculation
  • 3.http://www.ultradrive.com/bsac.htm BSA Calculation
  • 1.Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs. 1998;56:1019–38. doi: 10.2165/00003495-199856060-00006. [DOI] [PubMed] [Google Scholar]
  • 2.Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer. 1998;34:33–46. doi: 10.1016/S0959-8049(97)00340-7. [DOI] [PubMed] [Google Scholar]
  • 3.Ibrahim S, Honig P, Huang SM, et al. Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol. 2000;40:31–8. doi: 10.1177/00912700022008658. [DOI] [PubMed] [Google Scholar]
  • 4.Lichtman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control. 2000;7:548–56. doi: 10.1177/107327480000700606. [DOI] [PubMed] [Google Scholar]
  • 5.Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15:291–5. doi: 10.1093/annonc/mdh079. [DOI] [PubMed] [Google Scholar]
  • 6.Stevens LA, Coresh J, Greene T, et al. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–83. doi: 10.1056/NEJMra054415. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.druginfonet.com/ Drug Information (with specialist information)
  • 2.http://chemfinder.camsoft.com/ Data Base of Chemical Compounds
  • 3.http://www.meds.com/DChome.html Information on Cytostatics
  • 4.http://www.manuelsweb.com/IBW.htm IBW calculator
  • 5.http://medcal3000.com/CreatinineCl.htm Creatinine Clearance Calculator
  • 6.http://nephron.com/ GFR calculator
  • 1.Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol. 2004;15:146–50. doi: 10.1093/annonc/mdh009. [DOI] [PubMed] [Google Scholar]
  • 2.Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy. A French national survey. Cancer. 1999;86:2266–72. doi: 10.1002/(SICI)1097-0142(19991201)86:11<2266::AID-CNCR14>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  • 3.Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. Cancer. 2006;106:237–46. doi: 10.1002/cncr.21610. [DOI] [PubMed] [Google Scholar]
  • 4.Partridge AH, Garber JE. Long-term outcomes of children exposed to antineoplastic agents in utero. Semin Oncol. 2000;27:712–26. [PubMed] [Google Scholar]
  • 5.Salooja N, Szydio RM, Socie G, et al. Pregnancy outcomes after peripheral blood or marrow transplantation: a retrospective survey. Lancet. 2001;358:271–6. doi: 10.1016/S0140-6736(01)05482-4. [DOI] [PubMed] [Google Scholar]
  • 6.Williams SF, Schilsky RL. Antineoplastic drugs administered during pregnancy. Semin Oncol. 2000;27:618–22. [PubMed] [Google Scholar]
  • 1.http://www.cancer.gov/cancertopics/pdq/treatment/breast-cancer-and-pregnancy/ NCI Cancernet
  • 2.http://www.sogc.org/guidelines/public/111E-CPG-February2002.pdf SOGC Guideline
  • 1.Trissel LA. Handbook on Injectable Drugs. 14. Bethesda: American Society of Health-System Pharmacists; 2007. [Google Scholar]
  • 1.http://www.druginfonet.com/ Drug Information (with specialist information)
  • 2.http://chemfinder.camsoft.com/ Database of Chemical Compounds
  • 3.http://rxlist.com Internet Drug Index
  • 4.http://www.meds.com/DChome.html Information on Cytostatics
  • 1.ASCO Criteria for facilities and personnel for the administration of parenteral systemic antineoplastic therapy. J Clin Oncol. 2004;22:4613–5. doi: 10.1200/JCO.2004.05.077. [DOI] [PubMed] [Google Scholar]
  • 2.Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin. 2006;56:354–65. doi: 10.3322/canjclin.56.6.354. [DOI] [PubMed] [Google Scholar]
  • 3.Trissel LA. Handbook on Injectable Drugs. 14. Betherda: American Society of Health-System Pharmacists; 2007. [Google Scholar]
  • 1.http://www.druginfonet.com/ Drug Information
  • 2.http://www.meds.com/DChome.html Information on Cytostatics
  • 1.Boekhout AH, Beijnen JH, Schellens JHM. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist. 2006;11:641–54. doi: 10.1634/theoncologist.11-6-641. [DOI] [PubMed] [Google Scholar]
  • 2.Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol. 2003;30(suppl 14):3–11. doi: 10.1016/S0093-7754(03)00302-6. [DOI] [PubMed] [Google Scholar]
  • 3.Smith RE. A review of Selective Estrogen Receptor Modulators and National Surgical Adjuvant Breast and Bowel Projects clinical trials. Semin Oncol. 2003;30(suppl 16):4–13. doi: 10.1053/j.seminoncol.2003.08.002. [DOI] [PubMed] [Google Scholar]
  • 4.Writing Group for the Women’s Health Initiative (WHI) Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321–33. doi: 10.1001/jama.288.3.321. [DOI] [PubMed] [Google Scholar]
  • 5.Zlotta AR, Schulman CC. Neoadjuvant and adjuvant hormone therapy for prostate cancer. World J Urol. 2000;18:179–82. doi: 10.1007/s003450000119. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.prostateinfo.com/ Hormone Therapy in Prostate Cancer
  • 2.http://www.acor.org/TCRC/tclinks6.html Hormone Therapy in Testicular Tumors
  • 3.http://www.aace.com/ American Association of Clinical Endocrinologists
  • 4.http://www.duj.com/Article/Hellstrom2/
Hellstrom2.html Testosterone Replacement Therapy
  • 1.Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res. 2004;10(18 Pt 2):6342S–6S. doi: 10.1158/1078-0432.CCR-040029. [DOI] [PubMed] [Google Scholar]
  • 2.Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:314–20. doi: 10.1016/j.coph.2004.04.004. [DOI] [PubMed] [Google Scholar]
  • 3.Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11–22. doi: 10.1038/nrc1252. [DOI] [PubMed] [Google Scholar]
  • 4.Morcellin S, Rossi CR, Pilati P, et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth factor Rev. 2005;16:35–53. doi: 10.1016/j.cytogfr.2004.11.001. [DOI] [PubMed] [Google Scholar]
  • 5.Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8–32. doi: 10.1111/j.0105-2896.2004.00204.x. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.weizmann.ac.il/cytokine International Cytokine Society
  • 2.http://www.sciencedirect.com/science/journal/10434666 Cytokines Journal
  • 3.http://www.elsevier.com/wps/product/cws_home/868 Cytokine Growth Factor Reviews
  • 4.http://cytokine.medic.kumamoto-u.ac.jp Cytokine Family Database
  • 1.Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann Oncol. 2000;11(suppl 3):187–90. doi: 10.1023/A:1011144502974. [DOI] [PubMed] [Google Scholar]
  • 2.Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol. 2005;23:3235–42. doi: 10.1200/JCO.2005.08.409. [DOI] [PubMed] [Google Scholar]
  • 3.Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27. doi: 10.1200/JCO.2005.06.081. [DOI] [PubMed] [Google Scholar]
  • 4.Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54. doi: 10.1038/nrc1609. [DOI] [PubMed] [Google Scholar]
  • 5.López-Guillermo A, Mercadal S. The clinical use of antibodies in haematological malignancies. Ann Oncol. 2007;18(Suppl. 9):ix51–7. doi: 10.1093/annonc/mdm294. [DOI] [PubMed] [Google Scholar]
  • 6.Plosker G, Figgitt D. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803–43. doi: 10.2165/00003495-200363080-00005. [DOI] [PubMed] [Google Scholar]
  • 7.Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeuties. Nat Rev Drug Discov. 2007;6:349–355. doi: 10.1038/nrd2241. [DOI] [PubMed] [Google Scholar]
  • 8.Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003;30:424–33. doi: 10.1016/S0093-7754(03)00261-6. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.oncolink.upenn.edu Oncolink Information
  • 2.http://www.cancer.org/ American Cancer Society
  • 3.http://www.nci.nih.gov/ National Cancer Institute, Bethesda, USA
  • 4.http://www.fda.gov/cber/ FDA, Center for Biologics Evaluation and Research
  • 5.http://www.gallartinternet.com/mai Monoclonal Antibody Index
  • 6.http://www.cancerbackup.org.uk/treatments/
biologicaltherapies/monoclonalantibodies Cancer Backup UK
  • 7.http://en.wikipedia.org/wiki/
monoclonal_antibodies Wikipedia, Monoclonal Antibodies
  • 1.Bells HS, Ryan KM. Intracellular signalling and cancer: complex pathways lead to multiple targets. Eur J Cancer. 2005;41:206–15. doi: 10.1016/j.ejca.2004.10.022. [DOI] [PubMed] [Google Scholar]
  • 2.Benson C, Kaye S, Workman P, et al. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer. 2005;92:7–12. doi: 10.1038/sj.bjc.6602229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–53. doi: 10.1182/blood-2004-08-3097. [DOI] [PubMed] [Google Scholar]
  • 4.Ghobrial IM, Witzig TE, Adjej AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178–94. doi: 10.3322/canjclin.55.3.178. [DOI] [PubMed] [Google Scholar]
  • 5.Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol. 2005;23:3235–42. doi: 10.1200/JCO.2005.08.409. [DOI] [PubMed] [Google Scholar]
  • 6.Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003;102:2880–9. doi: 10.1182/blood-2003-02-0633. [DOI] [PubMed] [Google Scholar]
  • 7.Nencioni A, Grünebach F, Patrone F, et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia. 2007;21:20–6. doi: 10.1038/sj.leu.2404444. [DOI] [PubMed] [Google Scholar]
  • 8.Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18. doi: 10.1038/nrc1387. [DOI] [PubMed] [Google Scholar]
  • 9.Sabatini DM. mTOR and cancer. Nat Rev Cancer. 2006;6:729–34. doi: 10.1038/nrc1974. [DOI] [PubMed] [Google Scholar]
  • 1.http://cis.nci.nih.gov/fact/7_49.htm National Cancer Institute
  • 2.http://www.nature.com/nrc/focus/targetedtherapies Nature Reviews Cancer
  • 3.http://www.oncolink.com/treatment/treatment.cfm?c=12 Oncolink “Targeted Therapies”
  • 4.http://www.fda.gov/cder/drug/infopage/gleevec FDA, Glivec Information
  • 1.Dixon JR. The International Conference on Harmonization Good Clinical Practice Guideline. Qual Assur. 1998;6:65–74. doi: 10.1080/105294199277860. [DOI] [PubMed] [Google Scholar]
  • 2.EEC note for guidance good clinical practice for trials on medicinal products in the European Community. CPMP Party on Efficacy of Medicinal Products. Pharmacol Toxicol. 1990;67:361–72. doi: 10.1111/j.1600-0773.1990.tb00847.x. [DOI] [PubMed] [Google Scholar]
  • 3.Gajic A, Herrmann R, Salzberg M. The international quality requirements for the conduct of clinical studies and the challenges for study centers to implement them. Ann Oncol. 2004;15:1305–9. doi: 10.1093/annonc/mdh363. [DOI] [PubMed] [Google Scholar]
  • 4.Idanpaan-Heikkila JE. WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator. Ann Med. 1994;26:89–94. doi: 10.3109/07853899409147334. [DOI] [PubMed] [Google Scholar]
  • 5.World Medical Association . Helsinki Declaration, 1975. In: Beauchamp TL, Walters LW, editors. Contemporary Issues in Bioethics. 2. Belmont, CA: Wadsworth; 1982. [Google Scholar]
  • 1.http://eudract.emea.europa.eu/ European Clinical Trials Database
  • 2.http://www.clinicaltrials.gov US Clinical Trials Database
  • 3.http://www.controlled-trials.com/ Study Register
  • 4.http://www.centerwatch.com Clinical Trials Listing Service
  • 5.http://www.emea.europa.eu/ EMEA, European Agency for Evaluation of Medicinal Products
  • 6.http://www.fda.gov/ FDA, Food and Drug Administration, USA
  • 7.http://www.ich.org ICH, International Conf. Harmonization
  • 1.Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res. 2005;31:90–105. doi: 10.1016/j.mrfmmm.2004.07.025. [DOI] [PubMed] [Google Scholar]
  • 2.Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: roads to anticancer therapeutics nirvana? Oncogene. 2003;22:6621–8. doi: 10.1038/sj.onc.1206958. [DOI] [PubMed] [Google Scholar]
  • 3.Lee W, Lockhart AC, Kim RM, et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist. 2005;10:104–11. doi: 10.1634/theoncologist.10-2-104. [DOI] [PubMed] [Google Scholar]
  • 4.Loni L, De Braud F, Zinzani PL, et al. Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S115–22. doi: 10.1080/10428190310001623676. [DOI] [PubMed] [Google Scholar]
  • 5.Marsh S. Pharmacogenomics. Ann Oncol. 2007;18(suppl 9):ix24–8. doi: 10.1093/annonc/mdm289. [DOI] [PubMed] [Google Scholar]
  • 6.Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood. 2003;101:1270–6. doi: 10.1182/blood-2002-05-1600. [DOI] [PubMed] [Google Scholar]
  • 7.Tan BR, McLeod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol. 2005;32:113–9. doi: 10.1053/j.seminoncol.2004.09.029. [DOI] [PubMed] [Google Scholar]
  • 8.Weinshilboum R, Wand L. Pharmacogenomics: from bench to bedside. Nat Rev Drug Discovery. 2004;3:739–48. doi: 10.1038/nrd1497. [DOI] [PubMed] [Google Scholar]
  • 1.http:// www.nature.com/tpj/index.html Pharmacogenomics Journal
  • 2.http://www.ncbi.nlm.nih.gov/About/primer/pharm.html Pharmacogenomics Primer
  • 3.http://www.pharmgkb.org Pharmacogenetics Database
  • 4.http://www.nigms.nih.gov/Initiatives/PGRN Pharmacogenetics Research Network
  • 5.http://snp.cshl.org SNP Consortium

Articles from Concise Manual of Hematology and Oncology are provided here courtesy of Nature Publishing Group

RESOURCES